BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32330637)

  • 1. Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology.
    Nguyen HP; Go JA; Barbieri JS; Stough D; Stoff BK; Forman HP; Bolognia JL; Albrecht J;
    J Am Acad Dermatol; 2020 Aug; 83(2):691-699. PubMed ID: 32330637
    [No Abstract]   [Full Text] [Related]  

  • 2. Generic drugs in dermatology: part II.
    Payette M; Grant-Kels JM
    J Am Acad Dermatol; 2012 Mar; 66(3):353.e1-15; quiz 367-8. PubMed ID: 22342022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic drugs in dermatology: part I.
    Payette M; Grant-Kels JM
    J Am Acad Dermatol; 2012 Mar; 66(3):343.e1-8; quiz 351-2. PubMed ID: 22342021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The state and consequences of dermatology drug prices in the United States.
    Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
    J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
    [No Abstract]   [Full Text] [Related]  

  • 6. Generic drugs--safe, effective, and affordable.
    Peters JR; Hixon DR; Conner DP; Davit BM; Catterson DM; Parise CM
    Dermatol Ther; 2009; 22(3):229-40. PubMed ID: 19453347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding generics.
    Kircik LH
    J Drugs Dermatol; 2014 Jul; 13(7):s75-6. PubMed ID: 25007375
    [No Abstract]   [Full Text] [Related]  

  • 8. A Policy-Driven Perspective on Rising Drug Costs in Dermatology.
    Nguyen HP; Forman HP
    JAMA Dermatol; 2016 Jun; 152(6):625-6. PubMed ID: 27008060
    [No Abstract]   [Full Text] [Related]  

  • 9. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brand name versus generic drugs: the ethical quandary in caring for our sophisticated patients while trying to reduce health-care costs: facts and controversies.
    Payette M; Grant-Kels JM
    Clin Dermatol; 2013; 31(6):772-6. PubMed ID: 24160285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rise of the generic drug market and its implications for dermatology.
    Bhosle M; Balkrishnan R; Dewan T; Yelverton CB; Feldman SR
    J Dermatolog Treat; 2005; 16(5-6):295-8. PubMed ID: 16428148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New developments in pricing and drug reimbursement in France.
    Pelc A; Castan JP
    Pharmacoeconomics; 1994; 6 Suppl 1():28-35. PubMed ID: 10155583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the pharmaceutical industry in drug development in dermatology.
    Cauwenbergh G
    Clin Dermatol; 2002; 20(5):467-73. PubMed ID: 12435516
    [No Abstract]   [Full Text] [Related]  

  • 16. The future research agenda. A view from the pharmaceutical industry.
    Barr C
    Pharmacoeconomics; 1994; 6 Suppl 1():61-2. PubMed ID: 10155587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Myth of the Free Market for Pharmaceuticals.
    Conti RM; Frank RG; Cutler DM
    N Engl J Med; 2024 Apr; 390(16):1448-1450. PubMed ID: 38647106
    [No Abstract]   [Full Text] [Related]  

  • 19. Rising drug costs: the impact on dermatology.
    Rico MJ
    Skin Therapy Lett; 2000; 5(4):1-2,5. PubMed ID: 10785406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principles of economics crucial to pharmacy students' understanding of the prescription drug market.
    Rattinger GB; Jain R; Ju J; Mullins CD
    Am J Pharm Educ; 2008 Jun; 72(3):61. PubMed ID: 18698403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.